Pfizer tries not to be caught napping (CNN Money)
Pfizer could use a new blockbuster and the sleeping pill industry could use a new drug, and both could happen this summer if the FDA approves Indiplon at its review later this month.

Biogen Idec Needs a Booster (The Motley Fool)
In the large majority of circumstances, relationships between big bio-pharma companies and small biotechs are pretty asymmetrical. Sure, the big companies need new drugs, but they don't live and die on the success of a single drug (like so many biotechs).

VIVUS Announces Positive Phase 3 Clinical Trial Results For Evamist(TM) - The First Transdermal Spray For The Treatment (Medical News Today)
VIVUS, Inc.(Nasdaq: VVUS) today announced positive results from the pivotal Phase 3clinical trial of Evamist(TM). VIVUS' investigational estradiol metereddose transdermal spray is being developed for the treatment of vasomotorsymptoms associated with menopause. The study showed a statisticallysignificant reduction in the number and severity of moderate and severe hotflashes for all three doses